A long way into the quest to vanquish cancer, our ears strain to hear the words, “Cancer is cured”—a yearning that can cloud our judgment.

A drive for revenue is damaging basic science.

The nasal spray to ease intractable depression appears on the US market after decades without novel antidepressant treatments.

The deal between the two biopharmaceutical giants will boost the purchaser’s cancer drug portfolio.

YODA, a program facilitated by Yale University researchers, has successfully distributed clinical trial records from Johnson & Johnson and Medtronic to external researchers since 2013.

As Britain’s departure date from the European Union approaches, drugmakers are preparing for potential changes to regulatory procedures and border controls.

In efforts to translate basic-science results into pharmaceuticals and other technologies, success cannot be taken for granted.

The Ireland-based pharma company makes a $1.7 billion offer to acquire Tobira Therapeutics, a US firm developing liver disease drugs.

A move by the US federal government to close tax loopholes that encourage “tax inversions” likely spooked the companies out of the multibillion dollar deal.